Abstract
Oncological patients have a high risk of thrombotic complications, which worsen the outcomes of antitumor treatment and is one of the leading causes of death. Low molecular weight heparins are the main drugs for the prevention and treatment of thrombotic complications in cancer patients. Zibor (bemiparin) is a second-generation low-molecular-weight heparin (LMWH) that has the lowest molecular weight (3600 Dalton), a half-life increased to 5.3 hours and the highest anti-Factor Xa activity ratio (8:1). In clinical trials, bemiparin has demonstrated high efficacy and safety for prophylaxis and treatment of thromboembolic complications.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have